Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology develops a single-molecule proteome analysis platform for measuring proteins and proteoforms across the human proteome. Company news centers on the Voyager™ Platform, Iterative Mapping, the Tau Proteoforms assay, early access customer activity, and collaborations that apply isoform-resolved proteomics to cancer and neurodegenerative disease research.
Updates also cover quarterly financial results, operating outlook, commercial-readiness activity, senior sales leadership, scientific conference presentations, and investor-conference participation. The company's disclosures frame Nautilus as a development-stage life sciences tools business moving its proteomics platform from validation and field evaluation toward broader customer access.
Nautilus Biotechnology (NASDAQ: NAUT) has appointed Ken Suzuki as Chief Marketing Officer. Suzuki, a 25-year veteran from Agilent Technologies, brings extensive experience in mass spectrometry and proteomics to Nautilus, a company developing a single-molecule protein analysis platform. This strategic hire comes as Nautilus prepares to launch its Proteome Analysis Platform.
Suzuki's background includes leadership roles in Agilent's Mass Spectrometry division, Strategic Program Office, and Spectroscopy department. His expertise spans marketing, product development, finance, and R&D in the life sciences sector. Nautilus CEO Sujal Patel expressed enthusiasm about Suzuki's potential impact on bringing the company's platform to researchers worldwide.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management will engage in a fireside chat on September 4, 2024, at 7:00 a.m. Eastern Time.
This event presents an opportunity for investors and interested parties to gain insights into Nautilus's innovative proteomics platform. A live and archived webcast of the presentation will be accessible through the 'Investors' section of the company's website at www.nautilus.bio, allowing for widespread access to the discussion.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2024 financial results, showcasing progress in its single-molecule proteome analysis platform development. Operating expenses increased 9% to $20.8 million, primarily due to headcount growth. The company reported a net loss of $18.0 million, up from $15.8 million in the same period last year. As of June 30, 2024, Nautilus maintained a strong financial position with $232.9 million in cash, cash equivalents, and investments. CEO Sujal Patel emphasized the company's pioneering approach to overcome limitations in traditional protein analysis methods, focusing on both targeted proteoform analysis and broadscale discovery in proteomics.
Nautilus Biotechnology (NASDAQ: NAUT) has announced it will release its second quarter 2024 financial results on July 30, 2024, before the market opens. The company will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results, recent business developments, and future outlook. Interested parties can access the live audio webcast via the 'Investors' section of Nautilus' website at www.nautilus.bio.
Nautilus Biotechnology, a leader in single-molecule protein analysis, will join the Goldman Sachs 45th Annual Global Healthcare Conference. The event is set for June 10, 2024, at 8:40 a.m. ET. Nautilus' management will participate in a fireside chat, which will be available via live and archived webcast on their investor relations page.
Nautilus Biotechnology, Inc. reported its financial results for the first quarter of 2024, showing positive progress against core development goals. Operating expenses increased by 20% due to higher headcount for product development. Despite a net loss of $18.7 million, the company maintains a strong financial position with $247.7 million in cash, cash equivalents, and investments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.